by Truveta staff | May 2, 2024 | Research
Leading heart failure researchers have published new research in JACC: Heart Failure. The TREAT-AHF study found that despite significant efforts to improve acute heart failure treatment over the past 20 years, management remains unchanged. Reprieve Cardiovascular is...
by Michael Simonov, MD | Nov 8, 2023 | Data, News, Technology
When I had the first conversations about creating Truveta, I knew technology was the answer to solving healthcare data challenges. Healthcare data traditionally has been too siloed, inaccessible, and messy to be useful for research. And one of the biggest challenges...
by Truveta Research | Aug 23, 2023 | Research, Research Insights
The United States has some of the highest rates of adverse maternal health outcomes compared to other high-income countries (Creanga et al., 2015; Gunja et al., 2022; Taylor et al., 2022). These outcomes have only increased in the last decade (Hoyert, 2023; U.S....
by Truveta Research | Jul 10, 2023 | Research, Research Insights
We explored the demographic characteristics of patients with type 2 diabetes mellitus, heart failure, and chronic kidney disease who received a prescription for empagliflozin (Jardiance) and/or dapagliflozin (Farxiga), two commonly used SGLT2i drugs. We saw...
by Truveta staff | Feb 15, 2023 | News, Research
The United States is one of the most dangerous high-income countries in which to give birth. Nearly every negative maternal health outcome impacts women of color more than white women. This February, in honor of Heart Health Month and Black History Month, Truveta...
